National Aboriginal and Torres Strait Islander BBV and STI Strategy

National Aboriginal and Torres Strait Islander BBV and STI Strategy

 

The goals of the Fifth National Aboriginal and Torres Strait Islander BBV and STI Strategy are to:

  • Close the gap in BBV and STI incidence, prevalence, testing and treatment rates between Aboriginal and Torres Strait Islander and non-Indigenous populations;
  • Reduce morbidity and mortality related to BBV and STI;
  • Minimise the personal and social impact of BBV and STI;
  • Minimise the negative impact of stigma, racism, discrimination, and legal and human rights issues on Aboriginal and Torres Strait Islander people’s health.

Please find the link to the full Aboriginal and Torres Strait Islander BBV and STI Strategy document here.

 

Targets

The 15 targets of the National Aboriginal and Torres Strait Islander BBV and STI Strategy provide a specific focus for the efforts made towards achieving the goals of this Strategy:

  1. Achieve and maintain hepatitis B childhood vaccination coverage of 95% at 12 and 24 months of age
  2. Achieve and maintain HPV adolescent vaccination coverage of 80%
  3. Reduce the incidence and prevalence of infectious syphilis, gonorrhoea, chlamydia, with a focus on young people and areas of highest disease burden
  4. Increase STI testing coverage with a focus on areas of highest need
  5. Eliminate congenital syphilis
  6. Reduce the number of newly acquired hepatitis C infections by 60%
  7. Increase the use of sterile injecting equipment for every injecting episode
  8. Increase the proportion of people living with hepatitis C who are diagnosed to 90% and the cumulative proportion who have initiated direct acting antiviral  treatment to 65%
  9. Reduce hepatitis C attributable mortality by 30%
  10.  Increase the proportion of people living with hepatitis B who are diagnosed to 80%, receiving care to 50%, and on antiviral treatment to 20%
  11. Reduce hepatitis B attributable mortality by 30%
  12. Reduce the incidence of HIV transmissions
  13. Achieve the 95–95–95 HIV diagnosis and treatment targets
  14. Reduce the reported experience of stigma among Aboriginal and Torres Strait Islander people with BBV and STI, and the expression of stigma, in relation to BBV and STI status

 

Please note hereafter Aboriginal and Torres Strait Islander peoples will be respectfully be referred to as Indigenous people.

Indicators to monitor progress towards achieving the goals' targets are presented in the interactive dashboard below. Select the target and its indicators using the filter menu under the indicators table. Data sources are provided under the main tab for each indicator. Please note that data for Targets 9 and 11 as well as data for Indicators 6e, 8a, 8i, 11a and 13f are currently in development and will be presented on the dashboard as they become available.

 

These tables are interactive, allowing you to filter and present the data in detail.

  • Choose the category/populations of interest using the drop down menus.

  • Hover the mouse over the charts and tables to reveal further details.

  • These graphics are best viewed in full screen by clicking the box icon to the bottom-right of the tables.

  • You can export a PDF version of the selected view by selecting the download icon under the dashboard.

Click here for the executive summary: Tracking the Progress 2019: National Aboriginal and Torres Strait Islander BBV and STI Strategy

Data sourced from the National Notifiable Disease Surveillance System only include data provided by jurisdictions in which Aboriginal and Torres Strait Islander status was reported for ≥50% of diagnoses for each of the reported years. The jurisdictions whose data are represented in the reporting are listed by infection below:
  • Chlamydia: ACT, NT, Qld, SA and WA
  • Gonorrhoea: ACT, NT, Qld, SA, Tas, VIC and WA
  • Infectious syphilis: All jurisdictions
  • Hepatitis B (newly acquired and unspecified): ACT, NT, Qld, SA, Tas, VIC and WA
  • Hepatitis B (newly acquired only): NSW, NT, Qld, SA, Tas, VIC and WA
  • Hepatitis C (newly acquired and unspecified): ACT, NT, Qld, SA, Tas, VIC and WA
  • Hepatitis C (newly acquired only): All jurisdictions